New Technologies for Influenza Vaccines

Vaccine development has been hampered by the long lead times and the high cost required to reach the market. The 2020 pandemic, caused by a new coronavirus (SARS-CoV-2) that was first reported in late 2019, has seen unprecedented rapid activity to generate a vaccine, which belies the traditional vac...

Full description

Bibliographic Details
Main Authors: Steven Rockman, Karen L. Laurie, Simone Parkes, Adam Wheatley, Ian G. Barr
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Microorganisms
Subjects:
Online Access:https://www.mdpi.com/2076-2607/8/11/1745
id doaj-1716ea41f83e48b9baeaab7e4e19bf41
record_format Article
spelling doaj-1716ea41f83e48b9baeaab7e4e19bf412020-11-25T04:02:15ZengMDPI AGMicroorganisms2076-26072020-11-0181745174510.3390/microorganisms8111745New Technologies for Influenza VaccinesSteven Rockman0Karen L. Laurie1Simone Parkes2Adam Wheatley3Ian G. Barr4Technical Development, Seqirus Ltd, Parkville, VIC 3052, AustraliaTechnical Development, Seqirus Ltd, Parkville, VIC 3052, AustraliaTechnical Development, Seqirus Ltd, Parkville, VIC 3052, AustraliaDepartment of Immunology and Microbiology, The University of Melbourne, Parkville, VIC 3052, AustraliaDepartment of Immunology and Microbiology, The University of Melbourne, Parkville, VIC 3052, AustraliaVaccine development has been hampered by the long lead times and the high cost required to reach the market. The 2020 pandemic, caused by a new coronavirus (SARS-CoV-2) that was first reported in late 2019, has seen unprecedented rapid activity to generate a vaccine, which belies the traditional vaccine development cycle. Critically, much of this progress has been leveraged off existing technologies, many of which had their beginnings in influenza vaccine development. This commentary outlines the most promising of the next generation of non-egg-based influenza vaccines including new manufacturing platforms, structure-based antigen design/computational biology, protein-based vaccines including recombinant technologies, nanoparticles, gene- and vector-based technologies, as well as an update on activities around a universal influenza vaccine.https://www.mdpi.com/2076-2607/8/11/1745influenzavaccineuniversal vaccinecell-cultureegg-based influenza vaccinescell-based influenza vaccines
collection DOAJ
language English
format Article
sources DOAJ
author Steven Rockman
Karen L. Laurie
Simone Parkes
Adam Wheatley
Ian G. Barr
spellingShingle Steven Rockman
Karen L. Laurie
Simone Parkes
Adam Wheatley
Ian G. Barr
New Technologies for Influenza Vaccines
Microorganisms
influenza
vaccine
universal vaccine
cell-culture
egg-based influenza vaccines
cell-based influenza vaccines
author_facet Steven Rockman
Karen L. Laurie
Simone Parkes
Adam Wheatley
Ian G. Barr
author_sort Steven Rockman
title New Technologies for Influenza Vaccines
title_short New Technologies for Influenza Vaccines
title_full New Technologies for Influenza Vaccines
title_fullStr New Technologies for Influenza Vaccines
title_full_unstemmed New Technologies for Influenza Vaccines
title_sort new technologies for influenza vaccines
publisher MDPI AG
series Microorganisms
issn 2076-2607
publishDate 2020-11-01
description Vaccine development has been hampered by the long lead times and the high cost required to reach the market. The 2020 pandemic, caused by a new coronavirus (SARS-CoV-2) that was first reported in late 2019, has seen unprecedented rapid activity to generate a vaccine, which belies the traditional vaccine development cycle. Critically, much of this progress has been leveraged off existing technologies, many of which had their beginnings in influenza vaccine development. This commentary outlines the most promising of the next generation of non-egg-based influenza vaccines including new manufacturing platforms, structure-based antigen design/computational biology, protein-based vaccines including recombinant technologies, nanoparticles, gene- and vector-based technologies, as well as an update on activities around a universal influenza vaccine.
topic influenza
vaccine
universal vaccine
cell-culture
egg-based influenza vaccines
cell-based influenza vaccines
url https://www.mdpi.com/2076-2607/8/11/1745
work_keys_str_mv AT stevenrockman newtechnologiesforinfluenzavaccines
AT karenllaurie newtechnologiesforinfluenzavaccines
AT simoneparkes newtechnologiesforinfluenzavaccines
AT adamwheatley newtechnologiesforinfluenzavaccines
AT iangbarr newtechnologiesforinfluenzavaccines
_version_ 1724443715127214080